Why the study?
Does flecainide compared to propafenone improve the probability of safe and effective long-term treatment in patients with paroxysmal supraventricular tachyarrhythmias without structural heart disease?
Population
335 patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia, and no history…
Comparison
Flecainide, initial daily dose 100 mg for… vs Propafenone, initial daily dose 450 mg for both…
Design
RCT, randomized, parallel group, open label
Follow-up
12 months
Authors
Loading...
Supports either flecainide or propafenone; confirms comparable long-term outcomes in paroxysmal SVT and AF without structural heart disease.
Does flecainide compared to propafenone improve the probability of safe and effective long-term treatment in patients with paroxysmal supraventricular tachyarrhythmias without structural heart disease?
Flecainide and propafenone demonstrated comparable long-term safety and efficacy for the management of paroxysmal supraventricular tachyarrhythmias in patients without structural heart disease.
Chimienti et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: